视网膜静脉阻塞继发黄斑水肿的抗VEGF药物治疗进展  

Research progress on anti-VEGF drugs for macular edema secondary to retinal vein occlusion

作　　者：夏松[1] 陈有信[1] 

机构地区：[1]中国医学科学院北京协和医院,北京市100730

出　　处：《眼科新进展》2016年第11期1093-1096,共4页Recent Advances in Ophthalmology

摘　　要：视网膜静脉阻塞是一种常见的眼科疾病,黄斑水肿是其重要临床表现,对视力有重要损害。血管内皮生长因子(vascular endothelial growth factor,VEGF)在视网膜静脉阻塞继发黄斑水肿形成中可能具有重要作用,因此,抗VEGF药物的应用,提供了新的治疗手段,雷珠单抗、贝伐单抗、阿柏西普、康柏西普是临床上用于玻璃体内注射的主要抗VEGF药物,本文就各种抗VEGF药物的临床疗效作一综述。Retinal vein occlusion（ RVO） is a common disease. Macular edema is the important performance which leads to server visual loss. Vascular endothelial growth factor （VEGF） plays an important role in the development of RVO. The application of anti-VEGF drugs provides a new method for the treatment of macular edema. Ranibi- zumab, aflibercept, eonbercept are the main types of the anti-VEGF drugs, which are used for clinical treatment. This article reviews the clinical effects of various anti-VEGF drugs.

关 键 词：视网膜静脉阻塞 黄斑水肿 血管内皮生长因子 抗血管内皮生长因子 

分 类 号：R774.1[医药卫生—眼科]